

# Clinical trials of calcium sensitiser for acute heart failure in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 levosimendan

Trial	Treatments	Patients	Trials design and methods
<b>levosimendan vs placebo</b>			
<b>REVIVE-I , 2003</b> n=NA follow-up:	levosimendan 0.10.2 mg/kg/min versus placebo	patientst with HF andsymptoms at rest	Parallel groups
<b>REVIVE II , 2013</b> [NCT00048425] n=299/301 follow-up: 5 days	Intravenous Levosimendan versus placebo	patients with decompensated chronic heart failure	Parallel groups double blind
<b>RUSSLAN , 2002</b> n=NA follow-up: 14 days	Levosimendan at different doses (0.1-0.4 microg x kg(-1) x min(-1)) for 6h versus placebo	patients with left ventricular failure complicating acute myocardial infarction	Parallel groups double-blind
<b>levosimendan vs dobutamine</b>			
<b>CASINO</b> n=NA follow-up:	Levosimendan 16 mg/kg 0.2 mg/kg/min versus Dobutamine (10 mg/kg/min) and placebo	patients withdecompensatedlow-output HF	Parallel groups
<b>LIDO , 2002</b> n=NA follow-up: 24h	Levosimendan versus Dobutamine	patients with low-output heart failure	Parallel groups double-blind
<b>SURVIVE , 2007</b> [NCT00348504] n=664/663 follow-up: 180 days	Intravenous levosimendan versus intravenous dobutamine	patients hospitalized with acute decompensated heart failure who required inotropic support	Parallel groups double-blind 9 countries

## References

### REVIVE-I, 2003:

Packer M, Colucci WS, Fisher L. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE-1 study. (Abstract) J Card Fail 2003;9:S61

Dickstein K, Snapinn S How should we analyse hospitalizations in clinical trials? Eur Heart J 2003 Jan;24:24-5 [12559935]

Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T Effect of levosimendan on the short-termclinical course of patients with acutelydecompensated heart failure. JACC Heart Fail 2013;1:103-11 [24621834]

### REVIVE II, 2013:

Packer M. The Randomized multicenter EValuation of IntravenousleVosimendan Efficacy-2 (REVIVE-2) trial. Late-breaking Clinical Trials.

Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T Effect of levosimendan on the short-termclinical course of patients with acutelydecompensated heart failure. JACC Heart Fail 2013 Apr;1:103-11 [24621834] [10.1016/j.jchf.2012.12.004](https://doi.org/10.1016/j.jchf.2012.12.004)

**RUSSLAN, 2002:**

Moiseyev VS, Pder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). *Eur Heart J* 2002 Sep;23:1422-32 [[12208222](#)]

**CASINO, 0:**

Zairis MN ACC 53rd Annual Scientific Session: Abstract 835-6.

**LIDO, 2002:**

Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. *Lancet* 2002 Jul 20;360:196-202 [[12133653](#)]

**SURVIVE, 2007:**

Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Pder P, Kivikko M Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. *JAMA* 2007 May 2;297:1883-91 [[17473298](#)]

## 2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.